Epidemiology Articles
Gain free access to the latest articles on the NASH and NAFLD epidemic by a global expert community. ⌨
Asia, Middle East, North Africa: burden of NAFLD
Authors: Golabi P, Paik JM, AlQahtani S, et al.
Published in J Hepatol 2021
Using Global Burden of Disease data, P. Golabi et al. (Inova Health System, USA) aimed to assess the incidence, mortality, and disability-adjusted life years attributable to NAFLD-related liver complications in Asia, the Middle East and North Africa. As stated by the authors in their conclusion, “NAFLD is poised to contribute to a substantial...
Read MoreNAFLD/NASH: clinical, economical, and patient related burdens
Authors: Kabarra K, Golabi P, Younossi ZM.
Published in Endocr Connect 2021
In this review, the authors focus on NAFLD / NASH and its clinical, economical, and patient related burdens.
Read MoreNASH Epidemic: a call to action
Authors: Kanwal F, Shubrook JH, Younossi Z, et al.
Published in Gastroenterology 2021
NAFLD and NASH are common conditions with a rising burden. As pointed out by F. Kanwal et al. (Baylor College of Medicine, and Michael E. DeBakey Veterans Affairs Medical Center, Houston,USA), “yet there are significant management gaps between clinical guidelines and practice in patients with NAFLD and NASH. Further, there is no single...
Read MoreNAFLD unawareness in US adults
Authors: Alqahtani SA, Paik JM, Biswas R, et al.
Published in Mol Metab 2021
MAFLD is closely related to disturbances in systemic energy metabolism, including insulin resistance and atherogenic dyslipidaemia. This review by J. Heeren and L Scheja (University Medical Center Hamburg-Eppendorf, Germany) discusses recent research addressing lipoprotein metabolism in the context of MAFLD...
Read MoreGenetic and epigenetic factors determining NAFLD risk
Authors: Jonas W, Schurmann A.
Published in Mol Metab 2021
Predicting the individual risk of NAFLD and determining the probability of disease progression is the basis for further developing prevention and treatment strategies. This requires knowledge of the genetic and epigenetic modifiers of NAFLD for genotype-guided risk stratification...
Read MoreChildren with suspected NAFLD: negative for other causes of liver disease
Authors: Yodoshi T, Orkin S, Arce-Clachar AC, et al.
Published in Pediatrics 2021
T. Yodoshi et al. (Cincinnati Children's Hospital Medical Center, USA) aimed to determine the prevalence of alternative causes of liver disease in a multicenter, retrospective cohort of 900 children with overweight and obesity patients aged ≤18 years with overweight and obesity, referred for suspected NAFLD...
Treatment of 3 major risk factors and fibrosis stage regression
Authors: Yao VJH, Sun M, Rahman AA, et al.
Published in Clin Exp Hepatol 2021
Currently, no established hierarchy exists for the influence of metabolic risk factors on NAFLD progression. In this retrospective cohort study, V. J. H Yao et al. (CUNY School of Medicine/Sophie Davis Biomedical Education Program, New York, USA) investigated and ranked the independent and combined effects of three major risk...
Japan: NAFLD may affect half of the population by 2040
Authors: Ito T, Ishigami M, Zou B, et al.
Published in Hepatol Int 2021
In this systematic review and meta-analytic approach combining study level with individual patient-level data, T. Ito et al. (Nagoya University Graduate School of Medicine, Japan) aimed to investigate the epidemiology of NAFLD in Japan with a focus on lean NAFLD. The overall NAFLD prevalence was 25.5%, and increased over time...
Liver transplantation indications in Saudi Arabia: NASH has eclipsed HCV
Authors: Lee CO, Li HL, Tsoi MF, et al.
Published in Ann Med 2021
Our understanding of fatty liver syndromes and their relationship with the metabolic syndrome has improved over recent decades and, paralleling this, we are now at the dawn of the NAFLD (non-alcoholic fatty liver disease) to MAFLD (metabolic-associated fatty liver disease) transition...
Prevalence of NAFLD and MAFLD in the US population
Authors: Ciardullo S, Perseghin G.
Published in Liver Int 2021
S. Ciardullo et G. Perseghin (Policlinico di Monza, and University of Milano Bicocca, Italy) performed a cross-sectional study of adults recruited in the 2017-2018 NHANES Survey, a representative sample of the general US population, in order to determine the prevalence of NAFLD, MAFLD and associated advanced fibrosis in the US population...
NAFLD: a growing burden of disability
Authors: Paik JM, Golabi P, Younossi Y, et al.
Published in Hepatol Commun 2020
The burden of chronic liver disease varies according to aetiology and geographic location. J. M. Paik et al. (Inova Fairfax Medical Campus, Falls Church, VA, USA) assessed the global burden of disability from cirrhosis and liver cancer according to the most common aetiologies, between 2007 and 2017..
Global epidemiology of NAFLD-related HCC
Authors: Huang DQ, El-Serag HB, Loomba R
Published in Nat Rev Gastroenterol Hepatol 2021
In this Review, D. Q. Huang et al. (National University Health System, Singapore) discuss the global epidemiology, projections, and risk factors for NAFLD-related HCC, and propose preventive strategies to tackle this growing problem. The prevalence of NAFLD-related HCC is high in several regions worldwide...
SUBSCRIBE & FOLLOW US
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES